Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Targeting pathogenic Th17.1 cells via JAK-STAT3 pathway: A novel approach with tofacitinib for refractory myasthenia gravis.
Rui Zhao, Chong Yan, Huahua Zhong, Xiao Huan, Lei Jin, Dingxian He, Jianying Xi, Yarong Li, Baoguo Xiao, Feifei Luo, Chongbo Zhao, Jie Song, Sushan Luo
Published: 202610.1016/j.neurot.2026.e00831
Abstract
There remains a critical unmet need for effective, accessible, and well-tolerated therapies for myasthenia gravis (MG) who are refractory to current immunotherapies. The janus kinase and signal transducer and activator of transcription (JAK-STAT) sig…
Preview only. Read the full abstract at the source